TS-1 as first-line therapy for gastric linitis plastica: Historical control study

Anti-Cancer Drugs

Volumn 17, Issue 5, 2006, Pages 581-586

  Sasaki, Tohru ^a   Koizumi, Wasaburo ^a   Tanabe, Satoshi ^a   Higuchi, Katsuhiko ^a   Nakayama, Norisuke ^a   Saigenji, Katsunori ^a  

^a KITASATO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Gastric cancer; Linitis plastica; TS 1

Indexed keywords

5 2,4 DIHYDROXYPYRIMIDINE; CISPLATIN; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; TS 1; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES TUMOR; CANCER CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIARRHEA; DRUG ERUPTION; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HISTORICAL RESEARCH; HUMAN; LINITIS PLASTICA; LIVER DYSFUNCTION; LIVER METASTASIS; LOW DRUG DOSE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 33748190797     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200606000-00013     Document Type: Article

References (46)

1. Barwick KW. Linitis plastica: one disease or more? J Clin Gastroenterol 1982; 4:70-72.
2. Lauren P. The two main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64:31-49.
3. Ming SC. Gastric carcinoma: a pathobiological classification. Cancer 1977; 39:2475-2485.
4. Aranha GV, Georgen R. Gastric linitis plastica is not a surgical disease. Surgery 1989; 106:758-62; discussion 762-763.
5. Henson DE, Dittus C, Younes M, Nguyen H, Albores-Saavedra J. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type. Arch Pathol Lab Med 2004; 128:765-770.
6. Yokota T, Teshima S, Saito T, Kikuchi S, Kunii Y, Yamauchi H. Borrmann's type IV gastric cancer: clinicopathologic analysis. Can J Surg 1999; 42:371-376.
7. Bollschweiler E, Boettcher K, Hoelscher AH, Sasako M, Kinoshita T, Maruyama K, et al. Is the prognosis for Japanese and German patients with gastric cancer really different? Cancer 1993; 71:2918-2925.
8. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Noguchi Y. Should scirrhous gastric carcinoma be treated surgically? Clinical experiences with 233 cases and a retrospective analysis of prognosticators. Hepatogastroenterology 2001; 48:1509-1512.
9. Hamy A, Letessier E, Bizouarn P, Paineau J, Aillet G, Mirallie E, et al. Study of survival and prognostic factors in patients undergoing resection for gastric linitis plastica: a review of 86 cases. Int Surg 1999; 84:337-343.
10. Furukawa H, Hiratsuka M, Iwanaga T, Imaoka S, Ishikawa O, Kabuto T, et al. Extended surgery - left upper abdominal exenteration plus Appleby's method - for type 4 gastric carcinoma. Ann Surg Oncol 1997; 4:209-214.
11. Rougier P, Lasser P, Ducreux M, Mahjoubi M, Bognel C, Elias D. Preoperative chemotherapy of locally advanced gastric cancer. Ann Oncol 1994; 5(Suppl 3):59-68.
12. Rougier P, Mahjoubi M, Lasser P, Ducreux M, Oliveira J, Ychou M, et al. Neoadjuvant chemotherapy in locally advanced gastric carcinoma - a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum. Eur J Cancer 1994; 30A:1269-1275.
13. Rougier P, Ducreux M, Mahjoubi M, Pignon JP, Bellefqih S, Oliveira J, et al. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer 1994; 30A:1263-129.
14. Taguchi T, Inuyama Y, Kanamaru R, Hasegawa K, Akazawa S, Niitani H, et al. Phase I study of S-1. S-1 Study Group. Gan To Kagaku Ryoho 1997; 24:2253-2264.
15. Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mitachi Y, et al. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group. Oncology 1999; 57:202-210.
16. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998; 34:1715-1720.
17. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000; 58:191-197.
18. Koizumi W, Tanabe S, Kurihara M, Kondou I, Yamazaki I, Saigenji K. Pilot study of combined treatment with continuous infusion of 5-fluorouracil, mitomycin C, and cisplatin (FMP) in patients with inoperable advanced gastric cancer. Oncol Rep 1999; 6:643-646.
19. WHO.Handbook for reporting results of cancer treatment. Geneva: WHO; 1979.
20. Japanese Research Society for Gastric Cancer. Japanese classification of gastric carcinoma. Tokyo: Kanehara; 1995.
21. Japanese Society for Cancer Therapy. Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Chemother 1993; 28:101-130.
22. Ajani JA, Ota DM, Jackson DE. Current strategies in the management of locoregional and metastatic gastric carcinoma. Cancer 1991; 67(1 Suppl):260-265.
23. Moynihan T, Hansen R, Anderson T, Quebbeman E, Beatty P, Ausman R, et al. Continuous 5-fluorouracil infusion in advanced gastric carcinoma. Am J Clin Oncol 1988; 11:461-464.
24. Kaufman S. 5-Fluorouracil in the treatment of gastrointestinal neoplasia. N Engl J Med 1973; 288:199-201.
25. Schein PS, Macdonald JS, Hoth D, Wooley PV. Mitomycin C: experience in the United States, with emphasis on gastric cancer. Cancer Chemother Pharmacol 1978; 1:73-75.
26. Moertel CG, Lavin PT. Phase II-III chemotherapy studies in advanced gastric cancer. Eastern Cooperative Oncology Group. Cancer Treat Rep 1979; 63:1863-1869.
27. Lacave AJ, Wils J, Diaz-Rubio E, Clavel M, Planting A, Bleiberg H, et al. cis-Platinum as second-line chemotherapy in advanced gastric adenocarcinoma. A phase II study of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Eur J Cancer Clin Oncol 1985; 21:1321-1324.
28. MacDonald JS, Schein PS, Woolley PV, Smythe T, Ueno W, Hoth D, et al. 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 1980; 93:533-536.
29. Wils J, Bleiberg H, Dalesio O, Duez N, Blijham G, Planting A, et al. An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer. J Clin Oncol 1986; 4:1799-1803.
30. Lacave AJ, Baron FJ, Anton LM, Estrada E, De Sande LM, Palacio I, et al. Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial. Ann Oncol 1991; 2:751-754.
31. Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994; 5:609-616.
32. Murakami M, Ota K, Miyazaki T, Niitsu Y, Wakui A, Yokoyama M, et al. Sequential methotrexate-5-fluorouracil (MTX-5-FU) treatment of patients with advanced gastric and colorectal cancer. Sequential Methotrexate-5-FU Study Group. Gan To Kagaku Ryoho 1987; 14:2482-2490.
33. Konishi T, Hiraishi M, Mafune K, Miyama T, Hirata T, Mori K, et al. Therapeutic efficacy and toxicity of sequential methotrexate and 5-fluorouracil in gastric cancer. Anticancer Res 1994; 14(3B):1277-1279.
34. Koizumi W, Kurihara M, Satoh A, Takiuchi H, Tanabe S, Shimada K, et al. Phase 1/11 study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer. Anticancer Res 2005; 25(2B):1257-1262.
35. Ohtsu A, Boku N, Tamura F, Muro K, Shimada Y, Saigenji K, et al. An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 1998; 21:416-419.
36. Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 2005; 23:5660-5667.
37. Kinoshita T, Konishi M, Nakagohri T, Inoue K, Oda T, Takahashi S, et al. Neoadjuvant chemotherapy with S-1 for scirrhous gastric cancer: a pilot study. Gastric Cancer 2003; 6(Suppl 1):40-44.
38. Diasio RB. Oral DPD-inhibitory fluoropyrimidine drugs. Oncology (Huntingt) 2000; 14(10 Suppl 9):19-23.
39. Schmoll HJ. Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer. Anticancer Drugs 2003; 14:695-702.
40. Fujiwara H, Terashima M, Irinoda T, Takagane A, Abe K, Nakaya T, et al. Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity. Eur J Cancer 2003; 39:2387-2394.
41. Miyamoto S, Boku N, Ohtsu A, Yoshida S, Ochiai A, Okabe H, et al. Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer. Int J Oncol 2000; 17:653-658.
42. Usuki H, Ishimura K, Yachida S, Hagiike M, Okano K, Izuishi K, et al. Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines. Gastric Cancer 2003; 6(Suppl 1):66-70.
43. Miyamoto S, Ochiai A, Boku N, Ohtsu A, Tahara M, Yoshida S, et al. Discrepancies between the gene expression, protein expression, and enzymatic activity of thymidylate synthase and dihydropyrimidine dehydrogenase in human gastrointestinal cancers and adjacent normal mucosa. Int J Oncol 2001; 18:705-713.
44. Nakata B, Muguruma K, Yamagata S, Yukimoto K, Maeda K, Nishiguchi Y, et al. Differences in dihydropyrimidine dehydrogenase activities between gastric and colorectal cancer. Dig Dis Sci 2004; 49:60-64.
45. Ochiai T, Sugitani M, Nishimura K, Noguchi H, Watanabe T, Sengoku H, et al. Correlation between clinical pathophysiologic factors and expression of orotate phosphoribosyl transferase (OPRT), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer. Gan To Kagaku Ryoho 2002; 29:413-420.
46. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003; 89:2207-2212.